NCT04630067 - Assessment of Safety, Tolerability, Immunogenicity, and Pharmacokinetics of AZD3427 | Biotech Hunter

Enrollment

105

Participants

Timeline

Start Date

November 17, 2020

Primary Completion Date

September 14, 2022

Study Completion Date

September 14, 2022

Conditions

Heart Failure

Interventions

DRUG

AZD3427

Participants will receive SC or IV dose of AZD3427 as per the arm they are randomized.

DRUG

Placebo

Participants will receive SC or IV dose of placebo matched to AZD3427 as per the arm they are randomized.

Trial Locations (10)

Research Site, Brooklyn

Research Site, Daytona Beach

Research Site, Jacksonville

Research Site, Hallandale

Research Site, Doral

Research Site, Owensboro

Research Site, Detroit

Research Site, Little Rock

Research Site, Houston

Research Site, Glendale